Nxera Pharma Co., Ltd. (SOLTF)
OTCMKTS
· Delayed Price · Currency is USD
5.91
-0.49 (-7.66%)
Apr 23, 2025, 4:00 PM EDT
Nxera Pharma Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 36,203 | 49,065 | 66,557 | 60,087 | 40,008 | Upgrade
|
Cash & Short-Term Investments | 36,203 | 49,065 | 66,557 | 60,087 | 40,008 | Upgrade
|
Cash Growth | -26.21% | -26.28% | 10.77% | 50.19% | 160.22% | Upgrade
|
Accounts Receivable | 6,695 | 5,064 | 2,462 | 2,138 | 939 | Upgrade
|
Other Receivables | 4,643 | 6,823 | 140 | 103 | 732 | Upgrade
|
Receivables | 11,338 | 11,887 | 2,602 | 2,241 | 1,671 | Upgrade
|
Inventory | 8,838 | 2,903 | - | - | - | Upgrade
|
Prepaid Expenses | 1,259 | 790 | 638 | 388 | 322 | Upgrade
|
Other Current Assets | 217 | 467 | 145 | 92 | 17 | Upgrade
|
Total Current Assets | 57,855 | 65,112 | 69,942 | 62,808 | 42,018 | Upgrade
|
Property, Plant & Equipment | 7,468 | 7,900 | 3,791 | 3,817 | 3,824 | Upgrade
|
Long-Term Investments | 4,550 | 3,308 | 1,801 | 6,145 | 4,687 | Upgrade
|
Goodwill | 25,693 | 24,623 | 15,306 | - | - | Upgrade
|
Other Intangible Assets | 51,911 | 52,291 | 8,577 | 24,215 | 25,936 | Upgrade
|
Long-Term Deferred Tax Assets | 4,021 | 3,964 | - | - | - | Upgrade
|
Total Assets | 151,498 | 157,198 | 99,417 | 96,985 | 76,465 | Upgrade
|
Accounts Payable | 4,052 | 4,244 | 1,628 | 1,176 | 1,508 | Upgrade
|
Accrued Expenses | 1,250 | - | 400 | 570 | 167 | Upgrade
|
Current Portion of Long-Term Debt | 5,798 | 5,941 | - | - | - | Upgrade
|
Current Portion of Leases | 892 | 832 | 176 | 193 | 170 | Upgrade
|
Current Income Taxes Payable | 322 | 4,640 | 260 | 279 | 29 | Upgrade
|
Current Unearned Revenue | 3,141 | 1,388 | 1,450 | 785 | 784 | Upgrade
|
Other Current Liabilities | 177 | 140 | 178 | 4,188 | 327 | Upgrade
|
Total Current Liabilities | 15,632 | 17,185 | 4,092 | 7,191 | 2,985 | Upgrade
|
Long-Term Debt | 57,727 | 63,215 | 27,981 | 27,440 | 14,789 | Upgrade
|
Long-Term Leases | 3,483 | 3,985 | 1,577 | 1,638 | 1,664 | Upgrade
|
Long-Term Deferred Tax Liabilities | 1,857 | 1,490 | 2,922 | 2,706 | 2,457 | Upgrade
|
Other Long-Term Liabilities | 4,281 | 4,513 | 4,909 | 542 | 2,189 | Upgrade
|
Total Liabilities | 82,980 | 90,388 | 41,481 | 39,517 | 24,084 | Upgrade
|
Common Stock | 47,172 | 46,807 | 41,335 | 41,036 | 40,220 | Upgrade
|
Additional Paid-In Capital | 35,074 | 34,048 | 29,525 | 29,100 | 30,452 | Upgrade
|
Retained Earnings | -20,942 | -16,104 | -8,911 | -9,768 | -10,785 | Upgrade
|
Treasury Stock | -3 | -1 | -1 | - | - | Upgrade
|
Comprehensive Income & Other | 7,217 | 2,060 | -4,012 | -2,900 | -7,506 | Upgrade
|
Total Common Equity | 68,518 | 66,810 | 57,936 | 57,468 | 52,381 | Upgrade
|
Shareholders' Equity | 68,518 | 66,810 | 57,936 | 57,468 | 52,381 | Upgrade
|
Total Liabilities & Equity | 151,498 | 157,198 | 99,417 | 96,985 | 76,465 | Upgrade
|
Total Debt | 67,900 | 73,973 | 29,734 | 29,271 | 16,623 | Upgrade
|
Net Cash (Debt) | -31,697 | -24,908 | 36,823 | 30,816 | 23,385 | Upgrade
|
Net Cash Growth | - | - | 19.49% | 31.78% | 73.27% | Upgrade
|
Net Cash Per Share | -353.24 | -301.85 | 445.85 | 375.78 | 294.18 | Upgrade
|
Filing Date Shares Outstanding | 89.9 | 89.45 | 81.92 | 81.52 | 80.74 | Upgrade
|
Total Common Shares Outstanding | 89.9 | 89.45 | 81.92 | 81.52 | 80.6 | Upgrade
|
Working Capital | 42,223 | 47,927 | 65,850 | 55,617 | 39,033 | Upgrade
|
Book Value Per Share | 762.15 | 746.93 | 707.20 | 704.97 | 649.92 | Upgrade
|
Tangible Book Value | -9,086 | -10,104 | 34,053 | 33,253 | 26,445 | Upgrade
|
Tangible Book Value Per Share | -101.07 | -112.96 | 415.67 | 407.92 | 328.12 | Upgrade
|
Order Backlog | 1,122 | - | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.